SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

In a phase 2 trial, outpatients with Covid-19 who received a single infusion of a 2800-mg dose of the neutralizing antibody LY-CoV555 had a greater reduction from baseline in viral load than those who received placebo. Hospitalization was less frequent among antibody-treated patients (1.6% vs. 6.3%)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine Jg. 384; H. 3; S. 229 - 237
Hauptverfasser: Chen, Peter, Nirula, Ajay, Heller, Barry, Gottlieb, Robert L, Boscia, Joseph, Morris, Jason, Huhn, Gregory, Cardona, Jose, Mocherla, Bharat, Stosor, Valentina, Shawa, Imad, Adams, Andrew C, Van Naarden, Jacob, Custer, Kenneth L, Shen, Lei, Durante, Michael, Oakley, Gerard, Schade, Andrew E, Sabo, Janelle, Patel, Dipak R, Klekotka, Paul, Skovronsky, Daniel M
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Massachusetts Medical Society 21.01.2021
Schlagworte:
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Neutralizing - administration & dosage
Antibodies, Neutralizing - adverse effects
Asymptomatic
Clinical outcomes
Coronaviridae
Coronaviruses
COVID-19
COVID-19 - drug therapy
COVID-19 - virology
Disease
Dose-Response Relationship, Drug
Double-Blind Method
Emergency medical care
Female
Hospitalization - statistics & numerical data
Humans
Immunologic Factors - administration & dosage
Immunologic Factors - adverse effects
International organizations
Intravenous administration
Male
Medical research
Middle Aged
Monoclonal antibodies
Original
Outpatients
Pandemics
Patients
Placebos
Reverse Transcriptase Polymerase Chain Reaction
Ribonucleic acid
Risk factors
RNA
RNA, Viral - blood
SARS-CoV-2 - genetics
SARS-CoV-2 - isolation & purification
Severe acute respiratory syndrome coronavirus 2
Severity of Illness Index
Statistical analysis
Viral Load - drug effects
Young Adult
ISSN:0028-4793, 1533-4406, 1533-4406
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In a phase 2 trial, outpatients with Covid-19 who received a single infusion of a 2800-mg dose of the neutralizing antibody LY-CoV555 had a greater reduction from baseline in viral load than those who received placebo. Hospitalization was less frequent among antibody-treated patients (1.6% vs. 6.3%).
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
A list of the BLAZE-1 investigators is provided in the Supplementary Appendix, available at NEJM.org.
Drs. Chen and Nirula contributed equally to this article.
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2029849